Cheryl Lee, MD, reflects on her experience at ASCO 2022, a meeting at which she appreciated "the energy of 30,000 oncologists" and showcased new treatments and new therapies in the space of bladder cancer. In the non–muscle-invasive bladder cancer space, Dr Lee reviews the impressive outcomes from the QUILT-3.032 study which assessed the IL-15 superagonist N-803 in the treatment of BCG-unresponsive patients.
Next, Dr Lee reflects on the SWOG S1314 study, which looked at circulating-free DNA as a predictive biomarker of patient response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC). Finally, Dr Lee looks at the mixed results of two studies, the COSMIC-021 study and LEAP-011 trial, which assessed novel agents, yielding some potential benefits for more challenging MIBC patient populations.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASCO 2022: New Treatments and Novel Therapies in Advanced Bladder Cancer - Medscape - Jun 20, 2022.